Epicore BioNetworks IncTSXV: EBN

Epicore Signs Letter of Intent with IONA Contractors Ltd.

· Issued by Epicore BioNetworks Inc via CNW
CALGARY, Oct. 4 /CNW/ - The Board of Directors of Epicore BioNetworks
Inc. is pleased to announce that the Company has signed a letter of intent to
acquire ownership of all the shares of IONA Contractors Ltd. IONA is a
Calgary, Alberta, Canada based firm that focuses on providing construction
related services, including environmental remediation, to the oil and gas,
utility and other industries. The founders of IONA have over fifty years
experience in the environmental field. The acquisition will significantly
broaden Epicore's environmental business and provide a platform for further
growth in the future in the previously announced program that is spearheaded
by Board Director Frank D'Addario.
The acquisition purchase price is Cdn $1.4 million and one million
Epicore common shares at a deemed price of Cdn $0.14 per share. The purchase
is conditional on due diligence, financing, consideration of tax implications
and approval of the TSX Venture Exchange.
Epicore BioNetworks Inc. is a leading producer of environmental
biotechnology and animal nutrition products. It manufactures in the USA and
markets worldwide to a variety of industries to reduce environmental pollution
and increase operational productivity.

Epicore BioNetworks Inc. is a public corporation with a registered office
in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange
(symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.)

This press release contains forward-looking statements that involve
significant risks and uncertainties. The actual results, performance or
achievements of the Company might differ materially from the results,
performance or achievements of the Company expressed or implied by such
forward-looking statements. Such forward-looking statements include, without
limitation, those regarding the development plans of the Company and the
expected timing and results of such development. We can provide no assurance
that such development will proceed as currently anticipated or that the
expected timing or results of such development will be realized. We are
subject to various risks, including the uncertainties of product development,
markets for our products and regulatory review, our need for additional
capital to fund our operations, our reliance on collaborative partners, our
history of losses, and other risks inherent in the biotechnology industry.

Epicore BioNetworks Inc on 6ix

Earlier from Epicore BioNetworks

Later from Epicore BioNetworks

All Epicore BioNetworks news releases